Anne Li September 24th, 2017 firstname.lastname@example.org
Some lung cancer patients in England can now be offered a potentially life-extending immunotherapy drug. The National Institute for Health and Care Excellence( (NICE) has said that nivolumab (Opdivo) should be made available to certain lung cancer patients in England through the Cancer Drugs Fund (CDF). Rose Gray, Cancer Research UK’s senior policy adviser, welcomed the decision to provide the promising drug, which is a kind of immunotherapy.
See original article at: http://www.cancerresearchuk.org/about-us/cancer-news/news-report/2017-09-21-promising-immunotherapy-drug-now-available-for-some-lung-cancer-patients-in-england